Related Experiment Video

Updated: Jan 8, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

6.4K

Targeting the fibroblast growth factor receptor family in cancer

Niamh Hallinan1, Stephen Finn1, Sinead Cuffe1

  • 1Thoracic Oncology Research Group, Department of Clinical Medicine, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland.

Cancer Treatment Reviews
|April 26, 2016
PubMed

Insights

Fibroblast Growth Factor Receptor (FGFR) signaling is crucial in development and cancer. Aberrant FGFR signaling drives tumor growth, making FGFR a promising therapeutic target in solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • Fibroblast Growth Factors (FGFs) and their receptors (FGFRs) regulate critical biological processes.
  • Dysregulation of the FGF/FGFR signaling axis is implicated in various cancers, including squamous non-small cell lung cancer.
  • Genomic alterations in FGFR can lead to ligand-independent or ligand-dependent receptor activation, driving tumorigenesis.

Purpose of the Study:

  • To review the aberrant FGFR signaling pathway in solid tumors.
  • To explore the therapeutic potential of targeting FGFR in cancer treatment.
  • To discuss the interplay between FGFR and other signaling pathways like EGFR and VEGF.

Main Methods:

  • Literature review of studies on FGFR signaling in cancer.
  • Analysis of genomic alterations in FGFR across different tumor types.
  • Examination of preclinical and clinical data for FGFR-targeted therapies.

Main Results:

  • Aberrant FGFR signaling, driven by various genomic alterations, is a key mechanism in tumor development.
  • FGFR pathway interacts with VEGF and EGFR pathways, contributing to drug resistance.
  • Several FGFR-specific inhibitors and multi-target TKIs have shown promising preclinical results.

Conclusions:

  • Targeting aberrant FGFR signaling presents a viable therapeutic strategy for solid tumors.
  • Combinatorial approaches inhibiting FGFR, EGFR, and VEGF pathways may overcome drug resistance.
  • Ongoing clinical trials are evaluating the efficacy of FGFR-targeted therapies.
Keywords:
EGFRFGF ligandFGFRReceptor tyrosine kinaseTargeted therapy

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

5.0K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K